Navigation Links
ABAXIS Announces Appointment of Brenton Hanlon to Vice President of North American Medical Sales and Marketing
Date:8/10/2009

UNION CITY, Calif., Aug. 10 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced today the appointment of Brenton Hanlon to the position of vice president of North American medical sales and marketing, effective immediately. Mr. Hanlon, a member of the Abaxis Board of Directors since 1996, has resigned his position on the Board to assume this management/operational position within the Company.

Mr. Hanlon has been a medical diagnostic professional and corporate executive with more than 35 years of experience. He has a strong background in general management, marketing, sales, quality control and R&D experience with in-vitro diagnostics and medical companies.

From 2001 to August 2009, Mr. Hanlon served as president and chief executive officer of Hitachi Chemical Diagnostics, a manufacturer of in vitro allergy diagnostic products. Concurrently, from December 1996 until August 2009, Mr. Hanlon has served as president and chief operating officer of Tri-Continent Scientific, a subsidiary of Hitachi Chemical, specializing in liquid-handling products and instrument components for the medical diagnostics and biotechnology industries. From 1989 to December 1996, Mr. Hanlon was vice president and general manager of Tri-Continent Scientific. Mr. Hanlon serves on the board of directors of two privately-held companies.

Clint Severson, chairman and chief executive officer of Abaxis commented, "We are pleased to have an industry professional with the experience and skill set of Brenton Hanlon as our new vice president of North American Medical Sales and Marketing. Brenton has a long history of success in the industry and we believe he is uniquely qualified to lead Abaxis' sales and marketing initiatives into the future. His diagnostic industry expertise will be instrumental in the progression of Abaxis as a leading point of care technology provider. I look forward to working very closely with Brenton in the coming years."

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Private Securities Litigation Reform Act of 1995

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, risks involved in carrying of inventory, risks from unexpected problems or delays in the Company's manufacturing facility, risks associated with the ability to attract and retain competent sales personnel, general market conditions, competition, risks and uncertainties related to its ability to raise capital in order to fund its operations and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Contact:  Clint Severson             Lytham Partners, LLC
              Chief Executive Officer    Joe Dorame, Robert Blum and Joe Diaz
              Abaxis, Inc.               602-889-9700
              510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abaxis Reports Record Financial Performance for the First Quarter of Fiscal 2010
2. Abaxis to Report First Quarter Fiscal 2010 Financial Results Thursday, July 30, 2009
3. Abaxis, Inc. to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
4. Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2009
5. Abaxis to Report Fourth Quarter Fiscal 2009 Financial Results Wednesday, April 29, 2009
6. ABAXIS Realigns North American Medical Sales and Marketing
7. Abaxis, Inc. to Attend Lazard Capital Markets Medical Technologies Conference
8. Abaxis, Inc. to Present at Sidoti & Companys Thirteenth Annual New York Emerging Growth Institutional Investor Forum
9. Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009
10. ABAXIS Announces Launch of Two New Products at the NAVC
11. ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology: